Gilead shares rise after FDA approves cell-therapy drug Yescarta
October 18, 2017 at 18:20 PM EDT
Gilead Sciences Inc.’s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
